Inventiva S.A.

NASDAQ:IVA

Biotechnology

Healthcare
$3.39 +0.42%

+$0.02 today

Market cap
$176.22M
Beta
0.88
P/E (TTM)
-5.5
EPS (TTM)
-$0.56
52W Low $2.85High $7.98

Volume 3.54M

Average 0.45M

IVA Interest Income

Income earned on cash, deposits, and investments held by the company.

Inventiva S.A.NASDAQ: IVA

Interest Income · Q4 FY2025 · quarter ended Dec 2025

Interest income grows 47.5% year over year

Q4 FY2025 interest income of €1.69M rose 47.5% year over year. Over 3 fiscal years it compounded at +93.6% a year.

Context

  • Interest income amounted to 63.1% of revenue in FY2025, up 50.7 pp from a year earlier.
  • Interest income increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterDec 2025
€1.69M— QoQ
Last fiscal yearDec 2025
€2.83M+147.5% YoY
Interest Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+47.5%——
1 year+147.5%——
3-year CAGR+93.6%——
5-year CAGR——
10-year CAGR——

Interest Income history

EUR · from the income statement

Latest · FY2025
2.83M EUR
Year-over-year change
+147.5%
4-year CAGR
+165.4%

Interest Income vs competitors

How IVA compares with its peers on the latest reported figures

  • Peers report in different currencies, so interest income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +147.5% is the highest of 9, against a peer median of -25.9%.
  • Interest income amounts to 63.1% of revenue for IVA, versus a peer median of 12.9%.
IVA Competitors
Interest Income for IVA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ENTAEnanta Pharmaceuticals, Inc.LTM Mar 2026$8.9M USD-24.3%+82.0%12.9%
NAUTNautilus Biotechnology, Inc.LTM Mar 2026$7.08M USD-30.1%+10.6%—
RNACCartesian Therapeutics, Inc.LTM Mar 2026$5.59M USD-57.6%—314.9%
AVTXAvalo Therapeutics, Inc.LTM Mar 2026$4.01M USD-8.1%—6803.4%
IVVDInvivyd, Inc.LTM Mar 2026$3.62M USD+21.1%—6.5%
TNYATenaya Therapeutics, Inc.LTM Mar 2026$2.84M USD-27.6%+11.1%1262.2%
IVAInventiva S.A.FY2025€2.83M EUR+147.5%+93.6%63.1%
EPRXEupraxia Pharmaceuticals Inc.LTM Mar 2026$2.11M USD+71.2%+48.4%—
OBIOOrchestra BioMed Holdings, Inc.LTM Mar 2026$0 USD-100.0%—0.0%
CRBUCaribou Biosciences, Inc.LTM Mar 2026$0 USD—+20.3%0.0%
Peer median (excluding IVA) —-25.9%+20.3%12.9%

Competitors are the stored peer set for IVA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue4.19M12.18M17.48M9.2M4.48M
Cost of Revenue1.02M995K(23K)3.88M2.8M
Gross Profit4.19M17.06M17.5M9.2M1.51M
Gross Margin100.0%140.1%100.1%100.0%33.7%
Research & Development48.45M60.47M110.01M90.88M83.61M
Selling, General & Admin11.52M15.5M15.61M17.1M53.89M
Operating Expenses56.31M74.17M120.19M106.76M137.37M
Depreciation & Amortization858K870K2.6M5.2M2.8M
EBITDA(52.76M)(56.29M)(102.04M)(166.53M)(128.15M)
EBITDA Margin-1258.0%-462.2%-583.9%-1810.4%-2858.6%
Operating Income(52.11M)(57.11M)(102.71M)(97.56M)(130.95M)
Operating Margin-1242.6%-468.9%-587.7%-1060.6%-2921.0%
Interest Income57K390K945K1.14M2.83M
Interest Expense138K707K5.18M12.18M32.3M
Other Income / Expenses2.84M2.82M(7.11M)(86.34M)(211.38M)
Income Before Tax(49.27M)(54.29M)(109.82M)(183.9M)(342.33M)
Pre-Tax Margin-1174.8%-445.8%-628.4%-1999.4%-7636.1%
Income Tax Expense364K(20K)607K313K22K
Net Income(49.64M)(54.27M)(110.43M)(184.21M)(340.16M)
Net Margin-1183.5%-445.6%-631.8%-2002.7%-7587.8%
EPS (Basic)(1.27)(1.31)(2.43)(3.54)(1.82)
EPS (Diluted)(1.27)(1.31)(2.43)(3.54)(1.82)
Weighted Avg Shares39.17M41.45M45.35M51.98M186.8M
Weighted Avg Shares (Diluted)39.17M41.45M45.35M51.98M186.8M

Inventiva S.A.

NASDAQ:IVA

Intrinsic Alpha fair value

Locked

Current Price

$3.39

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.